A. Boehnke

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.

S. Mercadal, F. Merli, A. Davies, 2017, The Lancet. Haematology.

Preparation of phytantriol cubosomes by solvent precursor dilution for the delivery of protein vaccines.

T. Rades, T. Hanley, S. Hook, 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.

F. Merli, A. Davies, N. Siritanaratkul, 2014, The Lancet. Oncology.

Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis

R. Bergemann, S. Marx, J. Melnick, 2006, Clinical drug investigation.

Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development

A. Davies, P. Lugtenburg, S. Rule, 2017, Advances in Therapy.

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies

L. Gibiansky, P. N. Morcos, N. Frey, 2021, Clinical pharmacology and therapeutics.

Rituximab dosing in hematological malignancies: an old question, revisited

D. Mager, P. N. Morcos, N. Valente, 2019, Cancer Chemotherapy and Pharmacology.

Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: a qualitative study and the development of a patient-centred conceptual model

S. Acaster, K. Buesch, A. Boehnke, 2021, Journal of Patient-Reported Outcomes.